<DOC>
	<DOCNO>NCT01295697</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose EZN-2208 give pediatric patient Relapsed Refractory Solid Tumors . The safety study drug effect disease also study .</brief_summary>
	<brief_title>Study EZN-2208 Pediatric Patients With Solid Tumors</brief_title>
	<detailed_description>Pharmacokinetic ( PK ) test EZN-2208 , perform patient volunteer . PK test measure amount drug body different time point .</detailed_description>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients histologic verification malignancy original diagnosis relapse . Measurable evaluable disease Karnofsky score equal 50 patient &gt; 16 year age Lansky score equal 50 patient &lt; 16 year age Patients previously treat irinotecan eligible study document progressive disease treatment irinotecancontaining regimen . Adequate hematologic , hepatic , coagulation , renal , metabolic function Pregnant breast feeding patient enrol study Patients currently receive anticancer agent Patients uncontrolled infection Patients require cytochrome P450 3A4 enzyme induce inhibit agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Patients non-CNS CNS tumor</keyword>
	<keyword>Pediatric patient Relapsed/Refractory Solid Tumors</keyword>
</DOC>